For example: For all adults aged 60 and older, the societal cost per QALY saved was $196,842 for GSK's Arexvy and $176,557 for Pfizer's Abrysvo. For adults aged 65 and older, the cost was lower at ...

[34][35][36][37][38][39] The world’s first respiratory syncytial virus (RSV) vaccine for older adults Arexvy is registered for use in Canada, Australia, the US, the UK, the European Union, Japan and ...

Link to 47 Best Italian Horror Movies of All Time 30 Most Popular Movies Right Now: What to Watch In Theaters and Streaming Link to 30 Most Popular Movies Right Now: What to Watch In Theaters and ...

Advances in medical research have brought effective RSV vaccines to the market, such as Arexvy and Abrysvo. Neither is an mRNA vaccine, but both vaccines are indicated to prevent RSV in adults. The ...

GSK plc (LSE/NYSE: GSK) has received approval from the European Commission to extend the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, to adults aged 50-59 at increased risk of severe ...

The CDC recommends a single dose of either GSK’s AREXVY, Moderna’s mRESVIA or Pfizer’s ABRYSVO for all adults 75 years and older and adults between the ages of 60 to 74 who are at increased ...

The European Commission (EC) has authorised GSK’s Arexvy for active immunisation against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50 to ...